8538 Results for "

binding

" in MedChemExpress (MCE) Product Catalog:
Products (8538)

8538 Results for "binding" in MCE Product Catalog:

76
76 Cited Publications
Art. -Nr.: HY-17412A
CAS. Nr.: 10118-90-8
Minocycline is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect .
loading...
    loading...
75
75 Cited Publications
Art. -Nr.: HY-16141
CAS. Nr.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
75
75 Cited Publications
Art. -Nr.: HY-16143
CAS. Nr.: 199807-35-7
Synonyms: EMD 121974 TFA
Cilengitide TFA (EMD 121974 TFA) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide TFA inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide TFA inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide TFA can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors .
loading...
    loading...
71
71 Cited Publications
Art. -Nr.: HY-10211
CAS. Nr.: 75747-14-7
Reinheit:  99.01%
Synonyms: 17-AAG; NSC 330507; CP 127374
Forschungsgebiete:  

Infection Cancer

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .
loading...
    loading...
68
68 Cited Publications
Art. -Nr.: HY-14428
CAS. Nr.: 780757-88-2
Reinheit:  99.86%
Target:  

β-catenin Apoptosis

Forschungsgebiete:  

Cancer

ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
loading...
    loading...
68
68 Cited Publications
Art. -Nr.: HY-13067
CAS. Nr.: 34157-83-0
Reinheit:  99.64%
Synonyms: Tripterine; Tripterin
Celastrol (Tripterine;Tripterin) is a proteasome inhibitor which potently and preferentially inhibits the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. In addition, Celastrol is also an antibiotic with potent antimicrobial activity against standard and clinical methicillin-resistant Staphylococcus aureus (MRSA) strains, inducing oxidative stress and inhibiting DNA synthesis by binding to P5CDH .
loading...
    loading...
66
66 Cited Publications
Art. -Nr.: HY-16711
CAS. Nr.: 182498-32-4
Target:  

CXCR

SB225002, a potent, selective and non-peptide CXCR2 antagonist, inhibits 125I-IL-8 binding to CXCR2 with an IC50 of 22 nM.
loading...
    loading...
66
66 Cited Publications
Art. -Nr.: HY-135748A
Poly (I:C):Kanamycin (1:1) sodium is an isometric complex of Poly (I:C) (HY-135748) and Kanamycin (HY-16566). Poly(I:C) sodium, a synthetic analog of double-stranded RNA, is a TLR3 and retinoic acid-inducible gene I receptor (RIG-I and MDA5) agonist. Poly(I:C) sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses and induce apoptosis in cancer cells . Kanamycin is an orally active antibacterial agent (Gram-negative/positive bacteria) that inhibits translocation and causes miscoding by binding to the 70S ribosomal subunit. Kanamycin shows good inhibitory activity against Mycobacterium tuberculosis (susceptible and drug-resistant) and Klebsiella pneumoniae, and can be used in the research of tuberculosis and pneumonia .
loading...
    loading...
60
60 Cited Publications
Art. -Nr.: HY-17512
CAS. Nr.: 114798-26-4
Synonyms: DuP-753
Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
loading...
    loading...
60
60 Cited Publications
Art. -Nr.: HY-17512A
CAS. Nr.: 124750-99-8
Synonyms: DuP-753 potassium
Losartan potassium (DuP-753 potassium) is an angiotensin II receptor type 1 (AT1) antagonist, competing with the binding of angiotensin II to AT1 with an IC50 of 20 nM.
loading...
    loading...
57
57 Cited Publications
Art. -Nr.: HY-100514
CAS. Nr.: 1652591-81-5
Reinheit:  99.48%
GSK484 hydrochloride is a selective and reversible peptidylarginine deiminase 4 (PAD4) inhibitor. GSK484 hydrochloride demonstrates high affinity binding to PAD4 with IC50s of 50 nM in the absence of Calcium. In the presence of 2 mM Calcium, notably lower potency (250 nM) is observed.
loading...
    loading...
56
56 Cited Publications
Art. -Nr.: HY-13328
CAS. Nr.: 1224844-38-5
Reinheit:  99.63%
Synonyms: INK-128; MLN0128; TAK-228
Sapanisertib (INK-128; MLN0128; TAK-228) is an orally active dual mTORC1/mTORC2 inhibitor. Sapanisertib directly and simultaneously inhibits mTORC1/2 activity through competitive binding with ATP, thereby comprehensively blocking downstream processes such as protein and lipid synthesis and cytoskeletal reorganization, consequently suppressing tumor cell proliferation and promoting apoptosis. Sapanisertib is applicable to research on melanoma, ovarian cancer, pulmonary fibrosis, and hematological malignancies .
loading...
    loading...
55
55 Cited Publications
Art. -Nr.: HY-13992
CAS. Nr.: 195514-80-8
Reinheit:  99.85%
Synonyms: B/B Homodimerizer
Target:  

FKBP

Forschungsgebiete:  

Metabolic Disease

AP20187 (B/B Homodimerizer) is a cell-permeable ligand used to dimerize FK506-binding protein (FKBP) fusion proteins and initiate biological signaling cascades and gene expression or disrupt protein-protein interactions.
loading...
    loading...
53
53 Cited Publications
Art. -Nr.: HY-13956
CAS. Nr.: 111025-46-8
Reinheit:  99.89%
Synonyms: U 72107
Target:  

PPAR Ferroptosis

Forschungsgebiete:  

Metabolic Disease Cancer

Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
loading...
    loading...
52
52 Cited Publications
Art. -Nr.: HY-10010
CAS. Nr.: 461054-93-3
Reinheit:  99.97%
Target:  

BCRP

Forschungsgebiete:  

Cancer

Ko 143 is a potent and selective ATP-binding cassette subfamily G member 2 (ABCG2/BCRP) inhibitor. Ko 143 displays >200-fold selectivity over P-gp and MRP-1 transporters .
loading...
    loading...
52
52 Cited Publications
Art. -Nr.: HY-103666
CAS. Nr.: 1073612-91-5
Reinheit:  99.58%
Forschungsgebiete:  

Inflammation/Immunology

CY-09 is a selective and direct NLRP3 inhibitor. CY-09 directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation .
loading...
    loading...
52
52 Cited Publications
Art. -Nr.: HY-15084B
CAS. Nr.: 77086-21-6
Reinheit:  99.90%
Synonyms: MK-801
Target:  

iGluR

Forschungsgebiete:  

Neurological Disease

Dizocilpine (MK-801), a potent anticonvulsant, is a selective and non-competitive NMDA receptor antagonist, with a Kd of 37.2 nM in rat brain membranes. Dizocilpine acts by binding to a site located within the NMDA associated ion channel and thus prevents Ca 2+ flux .
loading...
    loading...
52
52 Cited Publications
Art. -Nr.: HY-B0573
CAS. Nr.: 318-98-9
Propranolol hydrochloride is a nonselective and BBB-permeableβ-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively. Propranolol hydrochloride inhibits [ 3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM. Propranolol hydrochloride is used for study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
loading...
    loading...
52
52 Cited Publications
Art. -Nr.: HY-B0573B
CAS. Nr.: 525-66-6
Propranolol is a nonselective and BBB-permeable β-adrenergic receptor (βAR) antagonist, has high affinity for the β1AR and β2AR with Ki values of 1.8 nM and 0.8 nM, respectively . Propranolol inhibits [ 3H]-DHA binding to rat brain membrane preparation with an IC50 of 12 nM . Propranolol is used for the study of hypertension, pheochromocytoma, myocardial infarction, cardiac arrhythmias, angina pectoris, and hypertrophic cardiomyopathy .
loading...
    loading...
52
52 Cited Publications
Art. -Nr.: HY-15676
CAS. Nr.: 1229705-06-9
Reinheit:  99.93%
Synonyms: RG7388
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors .
loading...
    loading...